进展期胃癌的分子靶向治疗进展

胃癌是目前世界上危害人类健康的主要疾病之一，不能手术切除的进展期胃癌预后较差，寻求手术以外途径治疗胃癌的转移、复发具有重要意义。分子靶向治疗具有分子特异性和选择性，能高效并选择性地抑制或杀伤肿瘤细胞，同时减少对人体正常组织的损伤，是目前肿瘤治疗领域发展的新方向。随着胃癌分子病理学的研究深入，针对进展期胃癌的分子靶向治疗的药物研发成功并开始走向临床。本文综合近年来较有影响力的临床试验，阐述靶向药物在进展期胃癌中的地位，其中，贝伐单抗、西妥昔单抗联合氟尿嘧啶、铂类、紫杉类药物均表现出较好的疗效和安全性。ＴｏＧＡ试验确立了曲妥珠单抗在治疗进展期胃癌上的地位，但靶向治疗药物在进展期胃癌治疗中广泛应用有赖于更多的临床试验证据支持。

Progression of molecular targeted therapy for advanced gastric cancer

Nowadays,gastric cancer is one of the world＇s major diseases that endanger human health,and the prognosis of unresectable advanced gastric cancer is dissatisfied.Therefore,it＇s very significant to find a new way other than operation to restrain the metastasis and recurrence of gastric cancer.The molecular targeted therapy is the current direction,for its molecule specificity and selectivity.Due to the two characteristics,molecule target therapy can kill tumor cells effectively and selectively,and reduce the damage to normal tissues.With the developmant of molecular pathology of gastric cancer research,the medicine for the molecule targeted therapy in advanced gastric cancer has successfully developed,and is applied in clinic.This essay will represent the important role of molecule target medicine in treating advanced gastric cancer by integrating the important clinical testes in recent years.Among these medicine,bevacizumab,cetuximab combined with fluorouracil,platinum or taxifolin have showed their efficacy and reliability.The ToGA test has made trastuzumab the important medicine in advanced gastric cancer treatment.Nevertheless,we need more evidence in clinical test to widen the use of the molecule target therapy in advanced gastric cancer treatment.